A Guide to America’s Seed Fund 2025 Virtual Tour Insights 🪴
INNOVATE Act: Reshaping America's Small Business Innovation Landscape 🚀
The Economic Cost of Cutting Government Research Funding: a Report
FDA Phasing Out Animal Testing
This roadmap outlines a strategic, stepwise approach for the FDA to reduce animal testing in preclinical safety studies with scientifically validated new approach methodologies (NAMs), such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays.
Federal agencies such as NIH and NSF are critical sources of funding for basic and applied scientific research. This brief describes a new analysis of the macroeconomic costs of cutting federal funding for scientific R&D. The brief finds that budget cuts to public R&D would significantly hurt the economy in the long run, with large negative effects on GDP, investment, and government revenue.
The recently introduced INNOVATE Act (Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence) represents the most significant overhaul of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs in years. The bill aims to reauthorize these critical innovation programs through 2028 while implementing substantial reforms.
The America’s Seed Fund 2025 Virtual Tour provided valuable insights into navigating the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Here is a cohesive summary of the key takeaways, organized into actionable sections.
The FDA's Commissioner's National Priority Voucher (CNPV) program provides a voucher to drug developers to speed up the review process for investigational new drugs (INDs) that align with U.S. national health priorities.
💊 The FDA has announced a new Commissioner's National Priority Voucher (CNPV) program designed to accelerate drug approvals for companies supporting U.S. national interests. The new voucher may be redeemed by drug developers to participate in a novel priority program that shortens FDA review time from approximately 10-12 months to 1-2 months.
New Commissioner's National Priority Voucher
